Form 4: Boston Scientific Executive Jeffrey Mirviss Reports Stock Transactions

Executive Vice President of Boston Scientific, Jeffrey Mirviss, reports acquisition and disposal of common stock and derivative securities.

Summary

• Jeffrey B. Mirviss, an Executive Vice President at Boston Scientific, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report includes transactions involving common stock and restricted stock units (RSUs).
• Mirviss acquired common stock through the vesting of RSUs on February 14, 16, and 17, 2025.
• He also disposed of common stock to cover tax obligations related to the vesting of these RSUs, with the stock sold at a price of $106.11 per share.
• Mirviss was granted 5,181 restricted stock units on February 13, 2025, which will vest in equal annual installments beginning February 13, 2026.
• He was also granted an option to purchase 13,334 shares of common stock on February 13, 2025, vesting in equal annual installments beginning February 13, 2026.
• Following these transactions, Mirviss directly owns 34,639 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Positives

• The granting of RSUs and stock options to executives can be seen as a positive incentive for performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's overall financial performance, but it does detail the future vesting schedules for stock options and restricted stock units granted to the reporting person.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies like Boston Scientific. These transactions are closely monitored by investors as they can provide insights into management's confidence in the company's future prospects. Form 4 filings are a standard part of regulatory compliance for company insiders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among large medical device companies such as Medtronic, Abbott, and Stryker.
• The vesting schedules and amounts of equity granted to executives are typically benchmarked against peer companies to ensure competitiveness and alignment with shareholder interests.
• The disposal of shares to cover tax obligations is a common practice among executives who receive equity compensation.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve the acquisition and disposal of shares by an executive.
• The granting of stock options and RSUs incentivizes the executive, potentially benefiting the company and its stakeholders.

Key Dates